STAT6 Degradation by KT-621 Correlates With Itch and Lesion Reduction in ADByJared Gollob, MD,Kaitlyn Bader, Assistant Managing EditorJune 3rd 2026
Topical GX-03 Hits 92.6% EASI-50 at Week 4 in Phase 2 AD InterimByMaddi Hebebrand, MC, Associate EditorJune 1st 2026
Soquelitinib Demonstrates Efficacy in Atopic Dermatitis After Systemic FailureByAlbert Chiou, MD, MBA,Kaitlyn Bader, Assistant Managing EditorMay 28th 2026
Zumilokibart Meets Primary and Secondary Endpoints in Phase 2 AD TrialByMaddi Hebebrand, MC, Associate EditorMay 27th 2026
JADE EXTEND Data Show Abrocitinib Efficacy Holds and Deepens Through 2 Years of TreatmentByMaddi Hebebrand, MC, Associate EditorMay 26th 2026